Want to see TSE:TELO full AI Analyst Report?
Top Page
Telo Genomics Corp
(TELO)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.05
▼(-2.00% Downside)
Action:Reiterated
Date:10/31/26
The score is primarily held down by weak financial performance—no revenue, ongoing losses, and increased balance-sheet stress with negative equity and higher debt—despite an improving cash burn trend in 2026. Technicals are mixed with mild longer-term support but near-term softness and oversold signals. Valuation contributes limited support given a negative P/E and no dividend yield provided.
Positive Factors
Specialized diagnostic platform
The TeloView platform gives Telo Genomics a defined technology base centered on telomere biology, with potential applications across oncology and hematology. This focused diagnostic capability can support development of specialized clinical and research products as the company advances commercialization.
Negative Factors
No revenue generation
The absence of reported revenue over multiple years indicates that Telo Genomics has not yet established commercial traction for its diagnostic offerings. Without recurring product or service sales, the company lacks an internal revenue engine to fund operations, validate demand, or support scalable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized diagnostic platform
The TeloView platform gives Telo Genomics a defined technology base centered on telomere biology, with potential applications across oncology and hematology. This focused diagnostic capability can support development of specialized clinical and research products as the company advances commercialization.
Read all positive factors
Telo Genomics Corp (TELO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.02M
Dividend YieldN/A
Average Volume (3M)68.96K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS Growth25.57%
CountryCA
Employees8
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding100,430,470
10 Day Avg. Volume12,102
30 Day Avg. Volume68,963
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-2.54
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Telo Genomics Corp Business Overview & Revenue Model
Company Description
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health ...
Telo Genomics Corp Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2026 | Sep 2025 | Sep 2024 | Jun 2022 | Sep 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -86.56K | -14.45K | -39.54K | -33.11K | -62.23K |
| EBITDA | -2.10M | -2.69M | -2.67M | -2.78M | -1.01M |
| Net Income | -2.31M | -2.72M | -2.71M | -2.82M | -1.07M |
Balance Sheet | |||||
| Total Assets | 599.90K | 911.30K | 965.64K | 2.93M | 3.84M |
| Cash, Cash Equivalents and Short-Term Investments | 338.32K | 789.29K | 796.02K | 2.67M | 3.64M |
| Total Debt | 1.44M | 0.00 | 0.00 | 32.50K | 40.00K |
| Total Liabilities | 2.18M | 396.32K | 375.59K | 312.87K | 153.66K |
| Stockholders Equity | -1.58M | 514.98K | 590.06K | 2.61M | 3.69M |
Cash Flow | |||||
| Free Cash Flow | -1.61M | -2.33M | -2.46M | -2.70M | -1.11M |
| Operating Cash Flow | -1.59M | -2.33M | -2.46M | -2.63M | -1.10M |
| Investing Cash Flow | -18.75K | -3.25K | -5.12K | -69.06K | -9.31K |
| Financing Cash Flow | 1.16M | 2.33M | 587.05K | 2.68M | 3.83M |
Telo Genomics Corp Technical Analysis
Positive
0.05
Price Trends
0.05
Positive
0.05
Positive
0.05
Positive
Market Momentum
<0.01
Positive
46.03
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.03 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TELO.
Telo Genomics Corp Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | C$5.02M | -2.17 | 295.03% | ― | ― | 25.57% | |
44 Neutral | C$6.32M | -2.84 | -241.33% | ― | -93.73% | -25.53% | |
43 Neutral | C$34.38M | -13.08 | 448.05% | ― | ― | 24.65% | |
42 Neutral | C$47.92M | -33.33 | -250.77% | ― | -82.05% | 23.73% | |
41 Neutral | C$7.18M | -2.40 | 273.53% | ― | ― | ― |
* General Sector Average
TSE:TELO
Telo Genomics Corp
0.05
0.00
0.00%
TSE:BUX
BioMark Diagnostics
0.45
0.11
32.35%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:KNE
Kane Biotech
0.04
<0.01
16.67%
TSE:SONA
Sona Nanotech Inc
0.28
-0.34
-54.84%
TSE:AVCR
Avricore Health
0.05
>-0.01
-9.09%
Telo Genomics Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Telo Genomics Expands Global Studies to Validate Blood-Based Myeloma MRD Test
Positive
Oct 29, 2026
Telo Genomics Corp. is a Vancouver-based diagnostics company developing diagnostic and prognostic tests that use three-dimensional analysis of telomeres, the ends of chromosomes. Its flagship liquid-biopsy assay, TELO-MRD, targets measurable resid...
Business Operations and Strategy
Telo Genomics’ Blood-Based TELO-MRD Shows Strong MRD Detection in Multiple Myeloma Comparisons
Positive
Sep 29, 2026
Telo Genomics has reported new clinical research results from its TELO-MRD program in multiple myeloma, comparing blood-based TELO enumeration of circulating plasma cells with bone-marrow Adaptive clonoSEQ next-generation sequencing. The company&#...
Business Operations and StrategyProduct-Related Announcements
Telo Genomics’ Blood-Based Myeloma Assay Outperforms Bone-Marrow MRD Test in Study
Positive
Sep 16, 2026
Telo Genomics reported clinical research results showing that its TeloView-based TELO-MRD blood assay detected residual multiple myeloma cells in a substantially higher proportion of matched samples than standard bone-marrow EuroFlow next-generati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.